MedWatch

ALK predicts 8–12 percent revenue growth in 2022

Allergy company ALK is expecting to reach an increase in revenue of 8–12 percent in local currencies in 2022, the company states in connection with full-year report on Tuesday.

Photo: ALK / PR

On Tuesday morning, ALK released the last quarterly figures for 2021, and therefore also for the entire year. In connection with the publication of the results, the allergy company has upgraded its guidance for the current financial year.

ALK is now expecting revenue growth of 8–12 percent in local currencies, which will primarily be driven by tablet sales growth, predicted to reach around 20 percent, according to ALK’s report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs